Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

Similar articles for PubMed (Select 11716188)

1.

Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions.

Tosteson AN, Jönsson B, Grima DT, O'Brien BJ, Black DM, Adachi JD.

Osteoporos Int. 2001;12(10):849-57.

PMID:
11716188
2.
3.

Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis.

Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M.

Health Technol Assess. 2007 Mar;11(7):iii-iv, ix-xi, 1-231. Review.

4.

Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women.

Lundkvist J, Johnell O, Cooper C, Sykes D.

Osteoporos Int. 2006 Feb;17(2):201-11. Epub 2005 Jul 19.

PMID:
16027955
5.

Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial.

Majumdar SR, Johnson JA, Lier DA, Russell AS, Hanley DA, Blitz S, Steiner IP, Maksymowych WP, Morrish DW, Holroyd BR, Rowe BH.

Osteoporos Int. 2007 Mar;18(3):261-70. Epub 2006 Nov 4.

PMID:
17086470
6.

Health-economic comparison of three recommended drugs for the treatment of osteoporosis.

Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E.

Int J Clin Pharmacol Res. 2004;24(1):1-10.

PMID:
15575171
7.

The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden.

Murphy DR, Smolen LJ, Klein TM, Klein RW.

BMC Musculoskelet Disord. 2012 Oct 30;13:213. doi: 10.1186/1471-2474-13-213.

8.

Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2006;6(20):1-180. Epub 2006 Nov 1.

9.

Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature.

Fleurence RL, Iglesias CP, Torgerson DJ.

Osteoporos Int. 2006 Jan;17(1):29-40. Epub 2005 Jun 25. Review.

PMID:
15981019
10.

The cost-effectiveness of bisphosphonates in postmenopausal women based on individual long-term fracture risks.

van Staa TP, Kanis JA, Geusens P, Boonen A, Leufkens HG, Cooper C.

Value Health. 2007 Sep-Oct;10(5):348-57.

PMID:
17888099
11.

An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials.

Borgström F, Jönsson B, Ström O, Kanis JA.

Osteoporos Int. 2006 Dec;17(12):1781-93. Epub 2006 Sep 29.

PMID:
17009083
12.

Cost-effectiveness of using clinical risk factors with and without DXA for osteoporosis screening in postmenopausal women.

Mueller D, Gandjour A.

Value Health. 2009 Nov-Dec;12(8):1106-17. doi: 10.1111/j.1524-4733.2009.00577.x. Epub 2009 Aug 10.

PMID:
19706151
13.

A multifaceted intervention to improve treatment of osteoporosis in postmenopausal women with wrist fractures: a cluster randomized trial.

Cranney A, Lam M, Ruhland L, Brison R, Godwin M, Harrison MM, Harrison MB, Anastassiades T, Grimshaw JM, Graham ID.

Osteoporos Int. 2008 Dec;19(12):1733-40. doi: 10.1007/s00198-008-0669-0. Epub 2008 Jul 16.

PMID:
18629567
14.

Partial adherence: a new perspective on health economic assessment in osteoporosis.

Kanis JA, Cooper C, Hiligsmann M, Rabenda V, Reginster JY, Rizzoli R.

Osteoporos Int. 2011 Oct;22(10):2565-73. doi: 10.1007/s00198-011-1668-0. Epub 2011 May 27. Review.

PMID:
21617992
15.

Pharmacoeconomic analysis of osteoporosis treatment with risedronate.

Brecht JG, Kruse HP, Felsenberg D, Möhrke W, Oestreich A, Huppertz E.

Int J Clin Pharmacol Res. 2003;23(4):93-105.

PMID:
15224498
16.

Fracture Reduction Affects Medicare Economics (FRAME): impact of increased osteoporosis diagnosis and treatment.

King AB, Saag KG, Burge RT, Pisu M, Goel N.

Osteoporos Int. 2005 Dec;16(12):1545-57. Epub 2005 Jun 8.

PMID:
15942702
17.

Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women.

Hiligsmann M, Reginster JY.

Bone. 2010 Jul;47(1):34-40. doi: 10.1016/j.bone.2010.03.009. Epub 2010 Mar 18.

PMID:
20303422
18.

The burden-of-illness study on osteoporosis in the Slovenian female population.

Dzajkovska B, Wertheimer AI, Mrhar A.

Pharm World Sci. 2007 Aug;29(4):404-11. Epub 2007 Feb 20.

PMID:
17310302
19.

Effectiveness and safety of vitamin D in relation to bone health.

Cranney A, Horsley T, O'Donnell S, Weiler H, Puil L, Ooi D, Atkinson S, Ward L, Moher D, Hanley D, Fang M, Yazdi F, Garritty C, Sampson M, Barrowman N, Tsertsvadze A, Mamaladze V.

Evid Rep Technol Assess (Full Rep). 2007 Aug;(158):1-235. Review.

20.

Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model.

Kreck S, Klaus J, Leidl R, von Tirpitz C, Konnopka A, Matschinger H, König HH.

Pharmacoeconomics. 2008;26(4):311-28.

PMID:
18370566
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk